Date: 2014-06-26
Type of information: Development agreement
Compound: two undisclosed biosimilar monoclonal antibody products
Company: Liomont (Mexico) Oncobiologics (USA - NJ)
Therapeutic area:
Type agreement: development manufacturing production commercialisation
Action mechanism: biosimilar/monoclonal antibody
Disease:
Details: * On June 26, 2014, Oncobiologics and Laboratorios Liomont S.A. de C.V. announced a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market. The scope of the agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics. Under the agreement, Liomont, a leading Mexico City-based pharmaceutical company, will provide Oncobiologics with upfront licensing and development milestone payments, as well as royalties once the medicines are commercialized. Oncobiologics will oversee global clinical trials and will provide commercial supply manufacturing for launch in the Mexican market.
Financial terms: Financial terms were not disclosed.
Latest news:
